Novo Nordisk (NVO) Fundamental Analysis: Revenue, Earnings & Valuation

6.56 / 10

Outperform

Fundamentally, Novo Nordisk earns an Outperform rating (6.6/10). Cost of sales (19%) and interest coverage (35x) are strong, while Days Sales Outstanding (83 days) and PB‑ROE (-0.64) are weaker. Overall outlook positive.

Analysis Checks(8/10)

Total operating revenue (YoY growth rate %)

Value6.43

Score2/3

Weight0.20%

1M Return0.07%

Days sales outstanding

Value83.17

Score1/3

Weight-4.51%

1M Return-1.61%

Accounts receivable turnover ratio

Value4.33

Score3/3

Weight-3.21%

1M Return-1.06%

Profit-MV

Value3.35

Score3/3

Weight38.51%

1M Return9.28%

PB-ROE

Value-0.64

Score0/3

Weight9.83%

1M Return2.91%

Income tax / Total profit (%)

Value21.53

Score3/3

Weight11.97%

1M Return3.28%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.93

Score2/3

Weight-3.63%

1M Return-1.25%

Operating revenue (YoY growth rate %)

Value6.43

Score2/3

Weight0.19%

1M Return0.06%

Cost of sales ratio (%)

Value19.02

Score3/3

Weight3.92%

1M Return1.16%

Asset-MV

Value-0.55

Score3/3

Weight46.73%

1M Return10.81%

Is NVO undervalued or overvalued?

NVO scores 6.56/10 on fundamentals and holds a Discounted valuation at present. Backed by its 60.70% ROE, 33.14% net margin, 10.18 P/E ratio, 5.37 P/B ratio, and 15.16% earnings growth, these metrics solidify its Outperform investment rating.